Novo Nordisk is chopping prices again for its popular obesity treatment Wegovy, but doctors say the expense will remain challenging for patients without insurance.

The drugmaker said Monday that it has started selling higher doses of the injectable treatment for $349 a month to patients paying the full bill. That’s down from $499 and in line with terms of a drug pricing agreement outlined earlier this month by President Donald Trump’s administration.

Novo also has started a temporary offer of $199 a month for the first two months of low doses of Wegovy and the drug’s counterpart for diabetes, Ozempic. The new pricing will be available at pharmacies nationwide through home delivery and from some telemedicine providers.

Rival Eli Lilly also plans price breaks for its weight-loss drug Zepb

See Full Page